Today, Analysts Review released its research reports regarding AbbVie Inc., Gilead Sciences Inc., Pfizer Inc., Eli Lilly and Company and Aetna Inc.. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7291-100free. AbbVie Inc. Research Report s On October 16, 2014, Bloomberg reported that AbbVie I
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed David J. Mauro, M.D., Ph.D., as Executive Vice President, Chief Medical Officer of Advaxis. Dr. Mauro brings to Advaxis more than 14 years of experience in oncology drug development, clinical research, and medical affairs
MedImmune licensed the OX40 agonist platform in 2011 from AgonOx as the result of a partnership between the Providence Cancer Center and AgonOx, a spin-off company from the Providence Cancer Center. Providence Cancer Center, one of the sites selected by MedImmune to participate in the clinical trial, has recently enrolled their first patient.
By a News Reporter-Staff News Editor at Biotech Business Week Amgen announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira in patients with moderate-to-severe plaque psoriasis met its primary endpoint. "Results from Amgen's biosimilar Phase 3 plaque psoriasis study met the primary endpoint
By a News Reporter-Staff News Editor at Biotech Business Week Amgen announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for the investigational bispecific T cell engager antibody construct, blinatumomab. As part of the acceptance, the FDA granted blinatumomab priority review with a Prescr
Apricus Biosciences, Inc., today announced that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator, fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland. Apricus Chief Executive Office, Richa
Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award with the California Institute of Regenerative Medicine, effective October 1, 2014. In August 2014, Asterias received clearance from the U.S. Food and Drug Administration to initiate the Phase 1/ 2 a clinical trial of AST-OPC1. "There are currently
Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's ANA 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease. By a News Reporter-Staff News Editor at Clinical Trials Week Avanir Pharmaceuticals, Inc. announced that data from the pha
By a News Reporter-Staff News Editor at Clinical Trials Week Avanir Pharmaceuticals, Inc. will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New York City. At the meeting, members of the Avanir senior management team will provide a company update and discuss the results from the phase II clinical trial eval
By a News Reporter-Staff News Editor at Pharma Business Week BioDelivery Sciences International, Inc. will host an investor update conference call and webcast to discuss the launch of BUNAVAIL? buccal film which has been approved by the U.S. Food and Drug Administration for the maintenance treatment of opioid dependence. Since FDA approval of B
Boehringer Ingelheim Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration approved OFEV capsules for oral use for the treatment of idiopathic pulmonary fibrosis. According to a release from the Company, granted Breakthrough Therapy designation during its review by the FDA, OFEV, capsules for oral use, taken twice daily, is the
By a News Reporter-Staff News Editor at Pharma Business Week BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the last patient has completed the last visit in its phase 2 a clinical trial of NurOwn? in Amyotrophic Lateral Sclerosis, conducted at the Hadassah Medical
Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo nivolumab in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer NSCLC. By a News Reporter-Staff News Editor at Pharma Business Week Bristol-Myers Squibb Company announced the establishment of a clinical trial collaboration to evaluate the safety,...
ChemoCentryx, Inc.,, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an inhibitor of the chemokine receptor known as CCR9. Data were presented at the 79th American College of Gastroenterolog
Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency for prevention of scarring post glaucoma filtration surgery. The orphan drug designation will significantly shorten a future market approval process and reinforce market exclusivity for a...
ClinTec International and Edinburgh Napier University's Masters Program Endorsed by Leading Multinational Top 20 Pharmaceutical Companies Through the Asia Training Consortium. By a News Reporter-Staff News Editor at Clinical Trials Week ClinTec International and Edinburgh Napier University are delighted to announce that the Asia Training...
Richmond Pharmacology has extended its capacity with an additional six-bed facility dedicated to screening and out-patient procedures for early phase studies in patients, complementing its existing 68- bed facility within Croydon University Hospital. Dr Keith Berelowitz, the Director of Operations commented: "It is the combination of medical...
Cytokinetics, Incorporated provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015.. BENEFIT-ALS is the first clinical trial in patients wi
Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-ALS Support Progression to Phase III Company Believes Effects on Slow Vital Capacity Could Support Registration Path For Tirasemtiv SOUTH SAN FRANCISCO, CA, October 20, 2014- Cytokinetics, Incorporated provided a program update today relating to tirasemtiv, the company's lead d
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1 b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society. The paper discusses results
Data on Clinical Trials and Studies Detailed by Researchers at Turku University Hospital. According to news reporting originating in Turku, Finland, by NewsRx journalists, research stated, "Early laryngeal cancer is usually treated with either transoral laser surgery or radiation therapy. The news reporters obtained a quote from the research from T
DGAP-News: MOLOGEN AG/ Key word: Study MOLOGEN AG: Successful investigator meetings for IMPALA colorectal cancer trial 20.10. 2014/ 08:00- Berlin, October 20, 2014- MOLOGEN AG, a biotechnology company focused on cancer immunotherapy, has organized the first set of investigator meet
Eisai Inc. announced today that the U.S. Food and Drug Administration accepted for review the company's Supplemental New Drug Application for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic seizures, a severe form of seizures, in patients 12 years and older. FYCOMPA? CIII, which
In the European Economic Area, Janssen is the marketing authorisation holder. Janssen affiliates market IMBRUVICA in EMEA as well as the rest of the world, except for the United States, where both companies co-market it. The decision from the European Commission follows a positive opinion from the Committee for Medicinal Products for Human Use of t
By a News Reporter-Staff News Editor at Clinical Trials Week BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the United States Food and Drug Administration has designated NurOwn? as a Fast Track product for the treatment of amyotrophic lateral sclerosis.